Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-04-14 M&A Activity
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 13, 2016, by Synta Pharmaceuticals Corp. It announces the entry into a material definitive agreement, specifically a merger agreement between Synta and Madrigal Pharmaceuticals. The document details the terms of the merger, voting agreements, financing arrangements, and changes in control and management resulting from the merger. It also includes information about unregistered sales of equity securities related to the merger and changes in the board of directors and executive officers. The content is focused on merger-related announcements and changes in control and management, not a full financial report or earnings release. Therefore, the document fits best into the category of M&A Activity (TAR) because it announces and describes a merger agreement and related transactions.
2016-04-14 English
8-K
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Synta Pharmaceuticals Corp. It details the entry into a material definitive agreement, specifically a merger agreement with Madrigal Pharmaceuticals, Inc. The text includes detailed descriptions of the merger terms, voting agreements, financing arrangements, and changes in control and management resulting from the merger. It also references proxy statements to be filed for shareholder approval. The content focuses on merger-related announcements, including changes in control and board composition, which are typical for M&A activity disclosures. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is not a proxy solicitation itself but references it. Given the detailed description of the merger agreement and related transactions, the appropriate classification is Merger & Acquisition (MA).
2016-04-14 English
10-K
Annual Report FY 2015
2016-03-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 25, 2016, reporting a workforce reduction plan and associated costs by Synta Pharmaceuticals Corp. It details the company's decision to reduce expenses through layoffs and estimates related severance and impairment charges. The content focuses on a specific corporate event (workforce reduction) and its financial impact, rather than presenting comprehensive financial statements or earnings results. This type of filing is a current report on a material event, which fits the category of Regulatory Filings (RNS) as it does not match other more specific categories like earnings releases or management reports. The document length is under 5,000 characters and is a standalone event disclosure, not an announcement of a report publication or a full report itself.
2016-03-01 English
FORM 4 -
Director's Dealing
2016-01-06 English
FORM 4 -
Director's Dealing
2015-12-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.